Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences, Inc. (VTYX)
NASDAQ:VTYX
VTYX Stock Chart & Stats
$14.00
-$0.21(-8.13%)
At close: 4:00 PM EST
$14.00
-$0.21(-8.13%)
Day’s Range― - ―
52-Week Range$0.78 - $25.00
Previous CloseN/A
Volume4.54M
Average Volume (3M)2.95M
Market Cap
$1.00B
Enterprise Value$982.56M
Total Cash (Recent Filing)$192.64M
Total Debt (Recent Filing)$10.02M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Mar 19, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding71,760,780
10 Day Avg. Volume4,203,254
30 Day Avg. Volume2,947,468
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.59
Price to Sales (P/S)0.00
P/FCF Ratio-1.14
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.65
Forecast
1Y Price Target
$13.38Price Target Upside-4.43% Downside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)-1.7
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition Validation And ResourcesEli Lilly's acquisition agreement validates NLRP3 as a therapeutic target and provides Ventyx programs access to Lilly's development and commercialization resources to advance into late-stage studies and potential market launch.
Clinical Efficacy SignalsPositive Phase 2 results for the central nervous system-penetrant candidate in obesity, cardiovascular risk and early Parkinson's support early anti-inflammatory efficacy and raise confidence in the program's therapeutic potential.
Global Trial Expansion And FormulationExpansion of the VTX2735 Phase 2 trial to international cohorts and introduction of a once-daily formulation could improve patient enrollment and adherence, supporting readiness for larger trials.
Bears Say
Deal Valuation And Shareholder UpsideThe acquisition terms establish a fixed value that caps upside for existing Ventyx shareholders and prompted analyst downgrades to a neutral or hold rating.
Operational Capacity And Cash RunwayLimited internal capacity and a constrained cash runway increased reliance on an external partner, which could make development timelines dependent on successful integration with the acquirer.
Regulatory And Closing RiskCompletion of the transaction requires regulatory and stockholder approvals, creating execution risk that the deal may not close as announced.
Ventyx Biosciences News
VTYX FAQ
What was Ventyx Biosciences, Inc.’s price range in the past 12 months?
Ventyx Biosciences, Inc. lowest stock price was $0.78 and its highest was $25.00 in the past 12 months.
What is Ventyx Biosciences, Inc.’s market cap?
Ventyx Biosciences, Inc.’s market cap is $1.00B.
When is Ventyx Biosciences, Inc.’s upcoming earnings report date?
Ventyx Biosciences, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 10 days.
How were Ventyx Biosciences, Inc.’s earnings last quarter?
Ventyx Biosciences, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.449 by $0.129.
Is Ventyx Biosciences, Inc. overvalued?
According to Wall Street analysts Ventyx Biosciences, Inc.’s price is currently Overvalued.
Does Ventyx Biosciences, Inc. pay dividends?
Ventyx Biosciences, Inc. does not currently pay dividends.
What is Ventyx Biosciences, Inc.’s EPS estimate?
Ventyx Biosciences, Inc.’s EPS estimate is -0.37.
How many shares outstanding does Ventyx Biosciences, Inc. have?
Ventyx Biosciences, Inc. has 71,760,780 shares outstanding.
What happened to Ventyx Biosciences, Inc.’s price movement after its last earnings report?
Ventyx Biosciences, Inc. reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.449. Following the earnings report the stock price went down -5.292%.
Which hedge fund is a major shareholder of Ventyx Biosciences, Inc.?
Currently, no hedge funds are holding shares in VTYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ventyx Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.38 (-4.43% Downside)
$13.38 (-4.43% Downside)
Blogger Sentiment
Bullish
VTYX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-45.35%
Trailing 12-Months
Asset Growth
-29.77%
Trailing 12-Months
Company Description
Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
VTYX Stock 12 Month Forecast
Average Price Target
$13.38
▼(-4.43% Downside)
Technical Analysis
Immutep
―
Voyager Therapeutics
―
Silence Therapeutics
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
9.81% Insiders
8.72% Mutual Funds
1.65% Other Institutional Investors
72.88% Public Companies and
Individual Investors